“The Bay Area is the largest biotech cluster in the world. We are happy to have made Fremont our home and are grateful for the support we have received from the community and the State of California,” said Jens Vogel, President and CEO of Boehringer Ingelheim Fremont, Inc. “We have made a commitment to the region and are excited to continue to invest in the Bay Area and expand our workforce to help increase patient access to high-quality medicines.”
“The State Treasurer’s Office is excited to play a role in helping Boehringer Ingelheim expand and create nearly 300 permanent, high-paying jobs right here in California,” said State Treasurer John Chiang. “The incentives my office provides ensure that California will retain and create jobs, bolster the economy and clean the environment, today and into the future.”
Boehringer Ingelheim is a research focused company who invests nearly 20% of all net sales back into research and development – that equates to nearly 20 cents on every dollar. The Fremont facility focuses on manufacturing medicines for immunology, rheumatology and oncology.
About the Company
Boehringer Ingelheim Fremont, Inc., based in Fremont, CA, is a human biologics manufacturing facility. With a diverse team of over 500 people, we cover biopharmaceutical development and manufacturing from small scale to commercial, from drug substance manufacturing to fill/finish, packaging and medical device assembly. Everything we do, we do to help patients – through the reliable supply of high quality medicines and being on the cutting edge of technology and innovation.
Founded in 1885, Boehringer Ingelheim is the largest family-owned and privately-held pharmaceutical company in the world with approximately 55,000 employees worldwide that focuses on both human and animal health. This allows the company to focus long-term and invest heavily in research and development in both human and animal medicine with its 16 facilities in the United States.
Learn more about Boehringer Ingelheim Fremont Inc., visit us at:
SOURCE Boehringer Ingelheim